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Abstract
Background: Systematic reviews of behaviour change interventions for smoking cessation vary in scope, quality,
and applicability. The current review aims to generate more accurate and useful findings by (1) a detailed analysis
of intervention elements that change behaviour (i.e. behaviour change techniques (BCTs)) and potential moderators
of behaviour change (i.e. other intervention and sample characteristics) and (2) assessing and controlling for variability
in support provided to comparison groups in smoking cessation trials.
Methods: A systematic review will be conducted of randomized controlled trials of behaviour change interventions for
smoking cessation in adults (with or without pharmacological support), with a minimum follow-up of 6 months,
published after 1995. Eligible articles will be identified through the Cochrane Tobacco Addiction Group Specialized
Register. Study authors will be asked for detailed descriptions of smoking cessation support provided to intervention
and comparison groups. All data will be independently coded by two researchers. The BCT taxonomy v1 (tailored to
smoking cessation interventions) and template for intervention description and replication criteria will be used to code
intervention characteristics. Data collection will further include sample and trial characteristics and outcome data
(smoking cessation rates). Multilevel mixed-effects meta-regression models will be used to examine which BCTs and/or
BCT clusters delivered to intervention and comparison groups explain smoking cessation rates in treatment arms (and
effect sizes) and what key moderators of behaviour change are. Predicted effect sizes of each intervention will be
computed assuming all interventions are compared against comparison groups receiving the same levels of
behavioural support (i.e. low, medium, and high levels). Multi-disciplinary advisory board members (policymakers,
health care providers, and (ex-)smokers) will provide strategic input throughout the project to ensure the review’s
applicability to policy and practice.
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Discussion: By capturing BCTs in intervention and comparison groups, this systematic review will provide more
accurate estimates of the effectiveness of smoking cessation interventions, the most promising BCTs and/or BCT
clusters associated with smoking cessation rates in intervention and comparison arms, and important moderators
of behaviour change. The results could set new standards for conducting meta-analyses of behaviour change
interventions and improve research, service delivery, and training in the area of smoking cessation.
Systematic review registration: PROSPERO CRD42015025251
Keywords: Smoking cessation, Systematic review, Meta-analysis, Meta-regression, Behaviour change technique,
Intervention, Comparison group, Control group, Randomized controlled trial, Tobacco
Background
Smoking is an important cause of preventable disease
and disability, which leads to a reduced quality of life
and life expectancy, an increase in health care burden,
and loss of productivity for society [1, 2]. Numerous be-
haviour change interventions for smoking cessation have
been developed and evaluated in randomized controlled
trials (RCTs). These trials have been synthesized in mul-
tiple systematic reviews including meta-analyses, which en-
able researchers, practitioners, and policymakers to draw
conclusions based on the totality of available evidence [3].
The strength of these meta-analyses lies in their ability to
identify the most effective interventions and to identify
intervention characteristics associated with greater inter-
vention effectiveness across settings and populations.
Recently, there have been two important methodological
developments in the field of systematic reviewing and
meta-analysis of behaviour change interventions that are
important to these outcomes but have not yet been applied
to smoking cessation trials. First, a more advanced system
for reliably specifying the content of behaviour change in-
terventions has been developed, resulting in more sophisti-
cated and informative meta-analyses of the active content
of behaviour change interventions [4–7]. The second
innovation builds on the first, but represents a step-change
in how we interpret and compare results from behaviour
change interventions in research syntheses. Comparison
groups, like intervention groups, often receive behavioural
support that varies considerably in content and effective-
ness between trials. Taking that into account in meta-
analyses can significantly alter conclusions about the ‘true’
effect sizes of interventions [5, 8, 9]. To present unbiased
and accurate recommendations about what interventions
work and under what conditions, it is vital to take variabil-
ity in comparison group contact into account [5, 8–11].
Evidence is accumulating that these innovations can
substantially advance the quality and usefulness of meta-
analyses by more accurately estimating true intervention
effects and the most effective elements of intervention
and comparison group treatment [5, 11–14]. The aim of
the current study is to adapt these innovative methods
and apply them in a comprehensive, state-of-the-art
systematic review and meta-analysis of smoking cessa-
tion interventions. This work could be a major step for-
ward in increasing the effectiveness of smoking cessation
RCTs and their applicability to practice.
Coding active content of interventions: behaviour change
techniques
Previous reviews have typically focussed on segments of
the smoking cessation literature, based on, for example,
‘by whom’ interventions were delivered (e.g. a physician,
pharmacist, nurse) [15–17], ‘how’ they were delivered
(e.g. face-to-face counselling, internet, telephone support)
[18–20], or ‘where’ they were delivered (e.g. workplace,
health, or community settings) [21, 22]. This approach is
limited in that it is unable to identify if these intervention
characteristics are important moderators of intervention ef-
fectiveness. Moreover, within these reviews, interventions
are often grouped based on fairly broad and heterogeneous
characteristics that do not describe intervention content in
sufficient depth. For example, stop smoking advice from
physicians is often termed ‘brief advice’ but may include
presenting a leaflet, individual counselling of varying dura-
tions, referral to smoking cessation programmes, or bio-
feedback using a carbon monoxide monitor [15]. Given
these differences in content and scope, it is unsurprising
that systematic reviews have observed significant variability
in effectiveness of ‘brief advice’ intervention (smoking ces-
sation rates of 0–20 % [15]). Currently, systematic reviews
only rarely focus on the active content of behaviour change,
called behaviour change techniques (BCTs), as a possible
explanation for this variability [4, 6, 7, 23].
BCTs constitute the smallest active ingredients of inter-
ventions capable of inducing change in behaviour in ap-
propriate circumstances [7]. For example, offering money
or vouchers for each month without smoking would be
coded as ‘material incentive’, and setting a quit date as
‘goal setting’. Achieving reliable coding of active content
of behaviour change interventions is complex; smoking
cessation interventions may employ up to 56 BCTs [24].
An extensive research programme has developed taxon-
omies of BCTs (with precise labels and definitions) which
achieve good reliability in coding BCTs from behaviour
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change intervention descriptions [25]. This work has
advanced research syntheses in fields such as medication
adherence and weight loss interventions, by describing
interventions in a replicable format and using meta-
regression to explore why interventions work (e.g. [5, 12–
14, 26]). This work includes a taxonomy for smoking ces-
sation interventions and studies examining how these can
be reliably applied [6, 25, 27–30]. We now propose to
conduct detailed content-coding of behaviour change in-
terventions for smoking cessation using the behaviour
change technique taxonomy version 1 (BCTTv1) [7] and
incorporate this in state-of-the-art meta-analyses in order
to identify what works best for whom under which cir-
cumstances. In addition to coding intervention content
(i.e. BCTs), we will use the template for intervention de-
scription and replication (TIDieR) to code other key inter-
vention characteristics that may serve as moderators of
BCT effectiveness, such as the setting, route of delivery,
and discipline and training of the person delivering the
intervention [31].
Coding active content of comparison groups
The second innovation applied in this project is to apply
the same rationale to comparison groups as to interven-
tion groups in trials of smoking cessation interventions
(i.e. to code BCTs and moderators of BCT effectiveness).
Comparison groups often also receive behavioural support
that may vary considerably in content and effectiveness.
Meta-analyses that do not account for this variability may
produce inaccurate estimates of intervention effects and
their active content [9]. We recently examined the con-
tent, variability, and effectiveness of BCTs provided to
comparison groups in behaviour change interventions for
the first time. Focusing on RCTs of counselling pro-
grammes to promote medication adherence, a reliable
index was developed for quantifying the active content
(weighting the number and type of BCTs delivered) of
what authors described as ‘usual/standard care’ provided
to comparison groups [5, 8]. This active content score var-
ied considerably between ‘treatment-as-usual comparison
groups’, was the main predictor of treatment success rates
in comparison groups [8], and in turn had an impact on
the effect sizes of interventions tested (i.e. effect sizes were
smaller in ‘treatment-as-usual settings’ where many BCTs,
often similar to those employed in interventions, were
already being delivered). This new method of assessing
the active content of comparison group support has made
it possible to obtain more valid estimates of the effective-
ness of the interventions tested (i.e. by adjusting interven-
tion effect estimates for the variability in support provided
to comparison groups), and the intervention ingredients
responsible for these effects [5, 8].
These procedures have not yet been applied in the field
of smoking cessation, yet there are strong indications that
comparison group variability is also relevant for evidence
syntheses of smoking cessation trials. First, current re-
views report substantial variability in the content and
scope of support provided to comparison groups (e.g. no
intervention, treatment-as-usual, self-help materials, infor-
mation only). Cochrane reviews investigating comparison
group characteristics define broad subgroups based on
intensity (e.g. number of sessions) or type (e.g. treatment-
as-usual versus self-help materials) rather than by their
active content (i.e. BCTs). Second, primary care smoking
cessation support outside the context of research trials
shows substantial variability in treatment-as-usual between
practices/practitioners (e.g. [32, 33]). Third, smoking cessa-
tion rates in comparison groups vary considerably within
and between comparison group types; in fact, comparison
group cessation rates are often comparable to those ob-
served in the intervention groups (e.g. 0–30 % for interven-
tion versus 0–28 % for comparison groups) [18]. These
data strongly suggest that when interpreting and compar-
ing effects of smoking cessation interventions, the active
content of support delivered to the comparison groups
should be taken into account; this might explain the ob-
served variability of success rates in comparison groups
and, consequently, in intervention effect sizes [5, 7–10].
Objectives
We propose to build on the most recent Cochrane reviews
of behaviour change interventions for smoking cessation
and introduce these methodological innovations in a com-
prehensive, rigorous systematic review.
The objectives are:
1. To examine whether variability in effectiveness of
smoking cessation interventions evaluated in RCTs
can be better explained through improved
characterization of the active content of:
a) The behaviour change interventions
b) The behavioural support provided to comparison
groups in these trials
2. To make recommendations to practitioners and
policymakers about the most effective ingredients of
behaviour change interventions for smoking
cessation, their impact, and the conditions under
which they are most likely to be effective
Research questions are:
1. Which BCTs and/or BCT clusters provided to
intervention and comparison groups explain
heterogeneity in smoking cessation rates in
intervention and comparison groups in RCTs on
smoking cessation interventions and in effect sizes?
2. What are the key moderators of effectiveness of
BCTs in smoking cessation interventions?
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3. To what extent are intervention effect sizes
influenced by differences in the behavioural support
provided to comparison groups in trials?
Methods
Reporting standards
The review is registered with PROSPERO (international
prospective register of systematic reviews) at the National
Institute for Health Research and Centre for Reviews and
Dissemination (CRD) at the University of York (registration
number CRD42015025251) and will be reported in accord-
ance with the PRISMA statement ([34], Additional file 1).
Overview of literature search
The Cochrane Tobacco Addiction Review Group Special-
ized Register (CTAGSR) (via the Cochrane Register of
Studies Online (CRSO) will be searched for studies pub-
lished from 1996 onwards (see http://onlinelibrary.wiley.
com/o/cochrane/clabout/articles/TOBACCO/frame.html).
This register is developed through continued and regular
electronic searching of MEDLINE, EMBASE, and Psy-
cINFO, together with hand searching of specialist journals,
conference proceedings, and reference lists of previous
trials and overviews. The CTAGSR is indexed on whether
or not studies are included in existing Cochrane reviews.
The current reviews’ inclusion criteria for study design,
population, and outcome are based on those used by the
Cochrane tobacco addiction group.
Search and screening process
Inclusion criteria
 RCTs with a minimum follow-up period of
6 months
 Interventions directed at adult smokers
 Trials describing (1) behaviour change interventions
with or without pharmacotherapy compared to (a)
different behaviour change interventions with or
without pharmacotherapy, (b) treatment-as-usual with
or without pharmacotherapy, (c) pharmacotherapy
alone, or (d) no treatment.
 Smoking cessation rates (primary outcome) reported
at least 6 months after the start of the intervention
 Trials published in peer-reviewed journals from
1996 onward
 Trials published in English
Trials describing behaviour change interventions, which
we have defined as ‘(a set of) materials and/or activities
designed to change behaviour through social and psycho-
logical processes’ [35, 36], will be included in our review.
Only trials published in the last 20 years will be consid-
ered for inclusion for two reasons. First, more recent trials
will be more relevant to current practice. Second, it was
judged to be unlikely we could retrieve accurate informa-
tion about intervention and comparison groups for trials
published longer ago. Only trials published in English will
be included, because no resources are available for the
translation of intervention and comparison group proto-
cols/materials, or the trial paper.
Searching and screening of the CTAGSR will be en-
hanced through use of existing Cochrane reviews using
the following procedures. First, all potentially relevant
references included in CTAGSR published from 1996
onward will be obtained (date initial search: 1-11-2015;
5989 references). Next, the study exclusion lists of pub-
lished Cochrane systematic reviews will be used to remove
studies based on shared inclusion/exclusion criteria (e.g.
follow-up shorter than 6 months, not an RCT). Third, all
remaining studies (titles and abstracts) will be screened in-
dependently by two reviewers (exclude at title/abstract
stage or proceed to full-text screening). Fourth, the full-
text published articles of references selected at title/ab-
stract stage will be assessed. Throughout this process data
will be managed using Covidence, Endnote, and MS Excel.
Since there is a substantial number of papers currently
included in the full-text screening phase (about 1500),
these papers will be divided into two sets: one set that is
double-screened and a set that is screened by one per-
son. To minimize the risk of eligible trials being ex-
cluded, and ineligible trials being included, the following
strategy will be used:
1. Paper titles will be organized using the standard
options in Covidence, the Cochrane systematic
review tool, and the first 200 papers will be selected
to be double-screened (eligible or not eligible) by the
three screeners working on this study (each screening
approximately 140 papers). Disagreements will be
discussed, and if not resolved, the third screener will
be consulted. The process includes reflection on biases
in the selection of papers leading to disagreements, in
particular regarding the exclusion of eligible trials.
Agreement will be considered satisfactory if
prevalence-adjusted bias-adjusted kappa (PABAK) is
>.80 (indicating excellent inter-rater reliability [37]). If
inter-screener agreement is unsatisfactory, the same
procedure will be repeated until satisfactory agreement
is achieved. If/when agreement is satisfactory, three
screeners will start to single-screen one third of all the
references. The screeners were instructed that in case
of uncertainty, they should include the paper with a
comment stating ‘Note sure’ to minimize the risk of
excluding eligible trials.
2. After the screeners have examined 50 % of their
papers, each will examine 30 randomly selected
papers (already screened) from one of the other
screeners, allowing for a repeated comparison of
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consensus on another 90 papers. The same
procedure will be applied for checking reliability as
in step 1.
3. All the papers included by one screener (i.e. eligible)
will be assigned to at least one other screener in the
data extraction phase, who will then confirm if study
inclusion was justified. Thus, all included papers will
have been included by two screeners, minimizing
the risk of including ineligible trials.
Data collection
Acquiring information about intervention and comparison
groups in included studies
The content of interventions, and especially of compari-
son group support, is usually described in insufficient de-
tail in published articles to allow coding of BCTs. Article
authors will therefore be contacted and asked to provide
additional materials that describe the intervention in more
detail. This can be the full intervention manuals, materials
(e.g. website content, folders), or materials to train profes-
sionals in the delivery of the intervention. We will first
contact authors by email (including reminders) and follow
up by telephone and/or fax if an author does not respond.
If the first author cannot be contacted, the second and last
authors will be approached.
Authors will also be asked for details regarding compari-
son group support, which may consist of (1) smoking cessa-
tion support introduced by researchers (e.g. self-help
materials)—for these, we will request all relevant manuals/
materials, similar to the interventions—and (2) treatment-
as-usual (TAU) smoking cessation support delivered to par-
ticipants by their health care providers during the study. As
TAU delivered in trials is typically not formally docu-
mented, a TAU checklist will be developed and sent to au-
thors to fill out. This checklist contains a comprehensive
list of TAU activities to support smoking cessation identi-
fied through (1) BCT coding four international stop smok-
ing treatment manuals [38–41]; (2) input from an advisory
board of (ex-)smokers, smoking cessation professionals,
and policymakers; (3) expertise in the team on smoking
cessation services, developed through previous studies (in-
cluding recording and BCT coding English smoking cessa-
tion service sessions [42]), and attending smoking cessation
sessions; and (4) smoking cessation example activities de-
scribed in previous (smoking cessation) BCT taxonomies
[6, 7, 42]. Only activities identified as the application of a
BCT will be included as an item in the checklist.
Study authors will be asked to indicate which activities
in the checklist were part of TAU. Activities that are con-
sidered to be part of TAU are those that have been ‘rou-
tinely delivered to the majority of comparison group
participants during the trial’. This approach to retrospect-
ively obtaining TAU information on comparison groups
proved feasible in previous reviews: data was obtained
from 67 % of the studies conducted in a clinical setting
and yielded data that was internally consistent (Cronbach
alpha >.90) with substantial predictive validity (i.e. vari-
ability in the scores on this checklist predicted substantial
variability in objective comparison group outcomes and
intervention effects) [5, 8]. Authors will also be asked
whether only the comparison group or also the interven-
tion group was exposed to TAU.
Data extraction
The following information will be coded independently
by two reviewers:
1. Sample characteristics and inclusion/exclusion
criteria.
2. Trial characteristics such as risk of bias (using the
Cochrane risk of bias tool [3], complemented with
elements described in the RATIONALE table [43])
and other potential effect modifiers.
3. Smoking cessation rates (objective and subjective
measures) at each time point reported. Secondary
outcomes are mortality and morbidity. Both
available case and intention-to-treat data will be
collected.
4. The active content (BCTs delivered to promote
smoking cessation) of the behavioural support
delivered to both intervention and comparison
groups will be coded from the treatment manuals/
materials and the TAU checklist, using the BCTTv1
([7]), which will be adapted to the smoking cessation
context, by adding smoking cessation examples of
BCTs (focused on quitting smoking, abstaining from
smoking, and medication adherence), introducing
new BCTs if identified in the coding process, and
removing BCTs irrelevant to smoking cessation
interventions. It will also be coded if
pharmacotherapy is used and what type of smoking
cessation medication is used.
5. Intervention and comparison group characteristics that
serve as potential moderators of BCT effectiveness,
such as the professional delivering the intervention,
setting, or the medium; duration of the intervention;
and tailoring and repetition of BCTs [5, 8, 31, 36].
6. Fidelity measures for intervention implementation.
Differences in data extraction for these variables will be
discussed by both coders until consensus is reached. If con-
sensus cannot be reached, the opinion of a third coder and,
if necessary, other members of the research team will be
consulted to determine the final decision. For each BCT
and coded moderator of smoking cessation support, inter-
rater reliability will be examined using adjusted Kappa sta-
tistics [37, 44]. Items with suboptimal reliability (i.e. <.7)
will be discussed with a third coder and, if necessary, the
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wider research team. Discrepancies that are not resolved
with high confidence (no agreement after discussion) and
items with low endorsement frequencies (present in <5 %
of the trials) will be noted but not used in further analyses.
Similar procedures will be used for the other elements,
such as risk of bias and fidelity measures.
Statistical analyses
Only eligible studies (i.e. that fit the inclusion criteria)
for which we are able to extract the primary outcome of
interest (i.e. cessation rate) for at least one study arm
and one time point and for which we are able to code
the intervention content will be included in the main
analyses.
Step 1: identifying the active components of smoking
cessation support provided to intervention and comparison
groups and their impact on effect sizes
BCTs may be examined individually, but as far as pos-
sible they will be analysed as clusters based on (i) behav-
ioural theory (e.g. [10]), (ii) cluster analyses (e.g. [45]),
and (iii) a sum score of all BCTs delivered, including a
weighting for delivery factors associated with outcomes
in step 2 (e.g. level of tailoring and repetition of BCTs,
e.g. 3). We will first examine which (clusters of) BCTs
delivered to intervention groups, and which (clusters of )
BCTs provided to comparison groups explain heterogen-
eity in smoking cessation rates in the respective arms.
For this, the cessation rates of both arms will be used as
the outcomes of interest and analysed by using an arm-
based multilevel mixed-effects meta-regression model that
allows the true rates of the intervention and comparison
group from the same study to be correlated [46, 47]. The
effects of (clusters of) BCTs on smoking cessation rates
will be allowed to differ between intervention and com-
parison groups by including a dummy variable indicating
the group and its interaction with the BCT cluster/moder-
ator score in the model. Hence, this model not only pro-
vides the information that a conventional mixed-effects
meta-regression analysis based on success rate differences
(i.e. the effect sizes) would offer but also (a) allows the in-
clusion of one-arm studies (e.g. when BCT clusters can
only be coded for the intervention or control arm of a
study) [47–49], (b) indicates which (clusters of) control
and intervention BCTs are related to cessation rates on an
absolute scale, and (c) can thus reveal which effective
(clusters of) intervention BCTs account for an increase in
effect sizes and what effective (clusters of) comparison
group BCTs account for a decrease in the effect sizes.
Time points used will be (at least) immediate post-
intervention (to identify BCT clusters related to initial
smoking cessation) and at the last follow-up (to identify
BCT clusters related to cessation maintenance), while
controlling for differences in follow-up duration between
studies. We will also explore the use of appropriate multi-
variate models to meta-analyse the entirety of the available
evidence at once (i.e. multiple time points) [50, 51].
Additionally, using an extension of the Egger regres-
sion test to an arm-based model, the presence of small-
study effects (which may be indicative of potential publi-
cation bias) will be examined by including the inverse
square root sample size and its interaction with the inter-
vention/comparison group dummy variable as predictors
in the meta-regression model [52]. A significant inter-
action would indicate that the size of the differences in
cessation rates between the intervention and comparison
groups is related to the standard errors by which the rate
differences are measured (and hence the statistical signifi-
cance of the cessation rate differences within studies).
Step 2: identifying moderators of BCT effectiveness
Key moderators of effective (clusters of) BCTs are inter-
vention attributes described in TIDieR, mainly setting,
provider, and route of delivery, and sample characteristics
such as socio-economic status or intention to quit smok-
ing at baseline. All analyses will be controlled for potential
covariates such as study design (e.g. risk of bias), sample
characteristics (e.g. age, gender, health status of partici-
pants), pharmacotherapy, and BCT co-occurrence and
take into account issues with multiple-testing [10].
Step 3: estimating intervention effect sizes adjusted for
comparison group variability
If the smoking cessation support provided to compari-
son groups varies between trials and impacts effect sizes,
we will compute an active content index (weighing (sets
of ) effective comparison group BCTs) and use the model
to compute the predicted effect size of each intervention
assuming it had been compared against similar compari-
son groups (i.e. under low, medium, or high amounts of
behavioural support) [3]. This model should provide a
more even-handed comparison of the effectiveness of
the various interventions than the currently published
evidence.
Advisory board
Multi-disciplinary advisory board members (policymakers,
health care providers, and (ex-) smokers) will provide es-
sential strategic input throughout the project to ensure the
review’s usefulness for policymakers, practitioners, and the
public (smokers). The advisory board will meet with mem-
bers of the research team three times during the project to
provide strategic input at specific stages of the project: dur-
ing (1) initial research design, (2) data analysis and inter-
pretation of results, and (3) research dissemination
planning. The first advisory board meetings have already
been held. Important contributions of advisory board mem-
bers have been an improvement of the selection of control
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variables and potential moderators of BCT effectiveness
and advising on the selection and phrasing of items for the
TAU activity list.
Data sharing
Data used in scientific manuscripts will be shared online
upon manuscript acceptance. Unused data will be pub-
lished online no later than 12 months after project com-
pletion (to permit the applicants to generate additional
scientific output).
Dissemination of findings
The results of this project will be published in international
peer-reviewed journals and presented at (inter)national sci-
entific conferences. A study website will be developed to
disseminate the results to researchers, policymakers, prac-
titioners, and the general public. Our advisory board will
provide recommendations and feedback regarding website
design and content, which will be tailored for specific audi-
ences. The policymakers’ section will contain a summary of
the main outcomes (including an evidence strength grad-
ing table) and study implications for policy and practice.
The researcher section will contain all data, measures,
computer programme syntaxes for statistical analyses, out-
puts, and published manuscripts. In case of evidence of
sufficient strength, the practitioners’ section will contain a
self-assessment tool for the active content of the smoking
cessation support currently provided and will provide feed-
back in the form of recommendations for increasing the ef-
fectiveness of their practice. Video examples of how to
deliver effective (clusters of) BCTs will support implemen-
tation of these recommendations. The general public sec-
tion will provide a summary of the project outcomes and
key recommendations, such as effective self-help strategies,
and referral to local smoking cessation services. Lastly, the
data and results (which will be assessed using GRADE cri-
teria [3]) will be sent to the appropriate bodies within and
outside of the UK for consideration in their guidelines for
smoking cessation support (e.g. National Institute for
Health and Care Excellence, UK; the UK National Health
Service Stop Smoking Services: Monitoring and Guidance;
Tobacco Use and Dependence Guideline Panel from the
US Department of Health and Human Services).
Discussion
By capturing BCTs in both intervention and comparison
groups, this systematic review advances current methods
and evidence and should provide more accurate estimates
of the true effectiveness of smoking cessation interventions
taking into account the diversity of comparison groups in
reported trials. It will identify the most promising (clusters
of) BCTs associated with smoking cessation rates and pin-
point important moderators of intervention effectiveness.
The results will yield valuable data for policymakers and
smoking cessation service providers, offering guidance
about effective support and about training needed for deliv-
ery of effective services. The methods developed in this
project could also set new standards for conducting system-
atic reviews and meta-analyses of behaviour change inter-
ventions and, more widely, in reviews of health care
interventions.
A number of challenges may arise while conducting this
systematic review, some of which warrant brief mention
here. In order to perform the review, we need additional in-
formation about intervention and comparison group sup-
port from a substantial number of authors of smoking
cessation RCTs. While some previous studies have yielded
a good author response rate [8, 53], it remains to be estab-
lished whether such response rates can be achieved in this
context. Although there are many eligible trials, substantial
difficulties in receiving additional materials from trial au-
thors may limit the power of the proposed analyses. In this
case, less elaborate analyses (i.e. fewer BCT predictors and
moderators), which require smaller sample sizes, will be
conducted. Similarly, comparison group data collected from
authors using the TAU checklist may be less accurate for
older than for recent studies. This issue can be explored by
examining whether the internal consistency of the TAU
checklist depends on publication year and by examining
the frequency of the number of ‘don’t know’ responses to
checklist items across publication years. If a potential issue
with reporting accuracy is identified, we will include an ‘ac-
curacy’ variable in the main analyses (e.g. the number of
‘don’t know’ responses in the TAU checklist) to see if this
affects the results. Another challenge may be that a larger
number of eligible trials is available than can be coded
using available resources (e.g. >200–250 trials). In this case
we will include those trials with a combination of high
methodological quality (e.g. trials with objectively verified
smoking cessation rates) and good information about inter-
vention and comparison groups and primary outcomes.
Conclusion
In summary, this systematic review has the potential to
identify what behavioural components of smoking cessa-
tion interventions work best for whom under which cir-
cumstances. The findings can inform future public health
practice and policy aimed at smoking cessation. Addition-
ally, the innovations applied in this study could set new
standards for meta-analyses, both in the field of smoking
cessation and in systematic reviews of health care inter-
ventions more generally.
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